A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with ß-thalassemia major

被引:8
|
作者
Elalfy, Mohsen S. [1 ]
Massoud, Walid [2 ]
Elsherif, Nayera H. [1 ]
Labib, Jonair H. [1 ]
Elalfy, Omar M. [1 ]
Elaasar, Safaa [3 ]
von Mackensen, Sylvia [4 ]
机构
[1] Ain Shams Univ, Pediat Thalassemia Ctr, Cairo, Egypt
[2] Amer Univ Cairo, Educ Testing & Assessment Div, Cairo, Egypt
[3] Ain Shams Univ, Dept Psychol, Fac Women, Cairo, Egypt
[4] Univ Med Ctr Hamburg Eppendorf UKE, Inst & Policlin Med Psychol Hamburg, Hamburg, Germany
关键词
adherence; ICT-Sat; iron chelators; patient-rated outcome; questionnaire; Thalassemia; QUALITY-OF-LIFE; BETA-THALASSEMIA; CARDIAC IRON; DESFERRIOXAMINE TREATMENT; OVERLOADED PATIENTS; DEFERASIROX; DEFERIPRONE; TRANSFUSION; DEFEROXAMINE; EFFICACY;
D O I
10.1002/pbc.23413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High satisfaction with iron chelation is a major determinant for adherence to ICT in beta-thalassaemia major (beta-TM) patients. In this study, a new tool to assess different domains of satisfaction for available forms of ICT was developed and validated. The impact of patients' satisfaction with ICT has been tested. Methods. Items were generated via focus groups and a preliminary version with 24 items (ICT-Sat) with an additional item for treatment preference and a knowledge questionnaire (KQ) was developed. 170 beta-TM patients from three Thalassaemia centers in Egypt, aged 2-32 years received three questionnaires to fill in; the new ICT-Sat, a KQ, and a previously validated tool for satisfaction with ICT (SICT) and retested 4-6 weeks later to ensure re-test reliability. Type of chelation, drug related adverse events, compliance with ICT, and serum ferritin level (SF) during the year prior to the study as well as available cardiac T2*data were recorded. Results. One hundred and fifty two beta-TM patients completed all questionnaires; median age was 12 years. The final 15 remaining ICT-Sat items, yielding to four domain scores, explained 70.6% of the total variance. The "perceived effectiveness" and "fear and worries" domains of the ICT-Sat correlated significantly with the domains "perceived effectiveness" and "acceptance" of the SICT. Patients treated with oral ICT were more satisfied with perceived effectiveness, and their side effects. Conclusions. A new clinically based ICT-Sat tool was developed and revealed good psychometric characteristics. Adherence to ICT was better correlated with "perceived effectiveness" and SF level. Pediatr Blood Cancer 2012; 58: 910-915. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 50 条
  • [21] CLINICAL-STUDIES ON IRON CHELATION IN PATIENTS WITH THALASSEMIA MAJOR
    FREEDMAN, MH
    OLIVIERI, N
    BENSON, L
    LIU, P
    MCCLELLAND, R
    STLOUIS, P
    TEMPLETON, D
    KOREN, G
    HAEMATOLOGICA, 1990, 75 : 74 - 83
  • [22] Long-Term Iron Chelation Therapy with Deferiprone in Patients with Thalassemia Major and Low Iron Load
    Daar, Shahina
    Al-Khabori, Murtadha K.
    Al Farsi, Khalil
    Al-Rawahi, Bader Abdulla
    Al-Riyami, Arwa Z.
    BLOOD, 2016, 128 (22)
  • [23] Myocardial iron loading in patients with thalassemia major on deferoxamine chelation
    Tanner, M. A.
    Galanello, R.
    Dessi, C.
    Westwood, M. A.
    Smith, G. C.
    Nair, S. V.
    Anderson, L. J.
    Walker, J. M.
    Pennell, D. J.
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2006, 8 (03) : 543 - 547
  • [24] Satisfaction with ICT predicts never thinking about stopping chelation therapy in patients with iron overload
    Rofail, D.
    Muriel, V.
    Baladi, J.-F.
    Brun, C.
    ANNALS OF ONCOLOGY, 2006, 17 : 193 - 193
  • [25] Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major
    Cohen, Alan R.
    Glimm, Ekkehard
    Porter, John B.
    BLOOD, 2008, 111 (02) : 583 - 587
  • [26] 844 Evaluation of Iron Chelation Therapy in Beta Thalassemia Major Patients in East Delta of Egypt
    M Badr
    M Hesham
    T Hassan
    S M Badawy
    Pediatric Research, 2010, 68 : 423 - 423
  • [27] Chelation therapy and cardiac status in young patients with thalassemia major
    Roodpeyma, S
    Alebouye, M
    Kamali, Z
    JOURNAL OF TROPICAL PEDIATRICS, 2000, 46 (03) : 179 - 179
  • [28] Transfusional Iron Overload and Iron Chelation Therapy in Thalassemia Major and Sickle Cell Disease
    Marsella, Maria
    Borgna-Pignatti, Caterina
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (04) : 703 - +
  • [29] Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial
    Hermine, Olivier
    Cappellini, Maria Domenica
    Taher, Ali T.
    Coates, Thomas D.
    Viprakasit, Vip
    Voskaridou, Ersi
    Lal, Ashutosh
    Liew, Hong Keng
    Perrotta, Silverio
    Khelif, Abderrahim
    Kattamis, Antonis
    Shetty, Jeevan K.
    Zhang, George
    Tian, Yu
    Miteva, Dimana
    Zinger, Tatiana
    Tang, Derek
    Backstrom, Jay T.
    Porter, John B.
    BLOOD, 2020, 136
  • [30] Assessing compliance to iron chelation therapy in patients with thalassemia.
    Pakbaz, Z
    Fischer, R
    Gamino, R
    Quirolo, K
    Yamashita, R
    Treadwell, M
    Fung, EB
    Harmatz, P
    Vichinsky, E
    BLOOD, 2004, 104 (11) : 33B - 33B